Browse the evidence

The incidence of peripheral neuropathy (PN) differs by type 2 diabetes (T2D) subgroup.

Healthcare providers should consider T2D subgroups when assessing PN risk.

GLP1-RA treatment is not associated with a significant difference in risk of serious psychiatric adverse events compared with placebo (log[RR] = -0.02; P = .87).

GLP1-RAs can be considered safe regarding serious psychiatric events in this population.

Patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) with a hazard ratio of 1.76.

Clinicians should monitor patients on semaglutide or tirzepatide for signs of NAION.

Patients prescribed semaglutide or tirzepatide had an increased risk of other optic nerve disorders with a hazard ratio of 1.65.

Clinicians should be aware of the risk of other optic nerve disorders in patients on semaglutide or tirzepatide.

Tirzepatide effectively attenuated the rewarding properties of alcohol, measured through locomotor stimulation, conditioned place preference, and accumbal dopamine release.

Tirzepatide may be a potential treatment for reducing alcohol consumption and its rewarding effects.

In women with type 2 diabetes, cardiovascular autonomic neuropathy (CAN) is significantly associated with an increased risk of all-cause mortality (CAN1: HR 1.64, CAN2: HR 1.58, CAN3: HR 1.78) and cardiovascular disease mortality (CAN1: HR 2.25, CAN2: HR 2.22, CAN3: HR 3.31).

Healthcare providers should prioritize monitoring CAN in women with type 2 diabetes to mitigate mortality risk.

GLP-1 receptor agonists (GLP-1RAs) may have neuroprotective and neurotrophic effects in ALS models.

GLP-1RAs may be considered for further investigation in ALS treatment.

Preoperative screening and interdisciplinary coordination are important for patients using GLP-1 RAs undergoing ophthalmic surgery.

Healthcare teams should ensure thorough preoperative assessments for these patients.

Increasing levels of neurofilament light chain (NfL) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.

Monitoring NfL levels may help in assessing cognitive decline in patients with T2D and obesity.

Increasing levels of glial fibrillary acidic protein (GFAP) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.

Tracking GFAP levels may provide insights into cognitive health in patients with T2D and obesity.

Individuals in the younger onset T2D subgroup have the lowest risk for peripheral neuropathy.

Younger individuals with T2D may require different monitoring for PN risk.

The impact of intensive lifestyle intervention (ILI) on peripheral neuropathy risk does not differ by T2D subgroups.

ILI may not be effective in reducing PN risk across different T2D subgroups.

A variety of clinical tools exist to assess nutritional status, sarcopenia, and physical frailty in liver transplant recipients.

Practitioners should utilize available assessment tools to evaluate frailty and nutritional status in liver transplant patients.